Scienture Holdings, Inc. (SCNX) is a Healthcare · Pharmaceutical Retailers company listed on NASDAQ. Price $0.32 (+0.86%), Market cap $0.02B, 52-week low–high $0.24 ~ $2.60.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-ac
Financial statements, price targets, institutional (13F) holdings and related news for Scienture Holdings, Inc. are updated in real time on BlackAll Trade.
Scienture Holdings, Inc. trades at $0.32 (+0.86%). Real-time quotes and charts are available on BlackAll Trade.
Scienture Holdings, Inc. has a market cap of about $0.02B.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the